Stifel Starts Moonlake Immunotherapeutics (MLTX) at Buy, 'View Sonelokimab as a Differentiated Asset We Can't Ignore'
Tweet Send to a Friend
(Updated - November 1, 2023 4:07 PM EDT)
Stifel analyst Alex Thompson initiates coverage on Moonlake Immunotherapeutics (NASDAQ: MLTX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
Stifel analyst Alex Thompson initiates coverage on Moonlake Immunotherapeutics (NASDAQ: MLTX) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
